Carmed Pharmaceuticals Expands to U.S. with CityBiz Feature

Carmed Pharmaceuticals, a Turkey-based science-driven company specializing in standardized carvacrol-based formulations, has earned editorial coverage in CityBiz through a featured executive Q&A with Founder Mustafa Can as the company continues expanding into the United States market. The interview explores Can's unconventional journey from ship master to founder of a research-focused pharmaceutical company built around standardized botanical formulations and long-term scientific development. The feature discusses Carmed's formulation philosophy, ongoing research initiatives, and strategy for entering the U.S. wellness market.

In the interview, Can explains how a personal interest in longevity and preventive wellness led him into years of independent research studying botanical compounds and formulation science before formally establishing Carmed Pharmaceuticals. The article highlights Carmed's emphasis on what the company describes as “rational synergy” - combining multiple bioactive compounds within standardized formulations designed around consistency, reproducibility, and analytical validation. The CityBiz placement comes as Carmed continues building awareness in the United States through a multi-channel distribution strategy that includes both curated wellness platforms and large-scale digital marketplaces. Several Carmed formulations are now available on OneLavi.com, including Vacrol Kids Spray, S-Mix, Vacrol Capsule, and Vacrol-M Capsule. Vacrol Kids Spray and S-Mix are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. The company also previously announced plans to expand availability through Amazon as part of its broader U.S. rollout strategy.

The CityBiz interview also discusses Carmed's commitment to scientific collaboration and ongoing research. In January 2026, research involving Carmed formulations Vacrol and S-Mix was published in the peer-reviewed journal Plants, where the formulations were examined in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based botanical formulations. The company emphasizes that this research reflects scientific investigation into formulation science and botanical bioactivity and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease. Carmed states that its U.S. strategy is focused on long-term brand development through scientific credibility, regulatory alignment, educational visibility, and expanded consumer accessibility. The full CityBiz Q&A with Mustafa Can can be viewed here. For more information, visit the Carmed Pharmaceuticals website.